466 related articles for article (PubMed ID: 27735912)
1. [Budget impact analysis of antiplatelet therapy with ticagrelor and clopidogrel in patients with acute coronary syndrome after coronary artery bypass surgery].
Zyryanov SK; Belousov DY; Afanasyeva EV; Dumchenko EV
Ter Arkh; 2016; 88(9):39-49. PubMed ID: 27735912
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of 12-month treatment with ticagrelor compared with clopidogrel in the management of acute coronary syndromes.
Liew D; De Abreu Lourenço R; Adena M; Chim L; Aylward P
Clin Ther; 2013 Aug; 35(8):1110-1117.e9. PubMed ID: 23891361
[TBL] [Abstract][Full Text] [Related]
3. Economic analysis of ticagrelor therapy from a U.S. perspective: results from the PLATO study.
Cowper PA; Pan W; Anstrom KJ; Kaul P; Wallentin L; Davidson-Ray L; Nikolic E; Janzon M; Levin LÅ; Cannon CP; Harrington RA; Mark DB
J Am Coll Cardiol; 2015 Feb; 65(5):465-76. PubMed ID: 25660925
[TBL] [Abstract][Full Text] [Related]
4. An Evaluation of the Cost-effectiveness of Comprehensive MTM Integrated with Point-of-Care Phenotypic and Genetic Testing for U.S. Elderly Patients After Percutaneous Coronary Intervention.
Okere AN; Ezendu K; Berthe A; Diaby V
J Manag Care Spec Pharm; 2018 Feb; 24(2):142-152. PubMed ID: 29384027
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of ticagrelor and generic clopidogrel in patients with acute coronary syndrome in Switzerland.
Gasche D; Ulle T; Meier B; Greiner RA
Swiss Med Wkly; 2013; 143():w13851. PubMed ID: 24089294
[TBL] [Abstract][Full Text] [Related]
6. Lifetime cost-effectiveness analysis of ticagrelor in patients with acute coronary syndromes based on the PLATO trial: a Singapore healthcare perspective.
Chin CT; Mellstrom C; Chua TS; Matchar DB
Singapore Med J; 2013 Mar; 54(3):169-75. PubMed ID: 23546032
[TBL] [Abstract][Full Text] [Related]
7. Direct healthcare costs and cost-effectiveness of acute coronary syndrome secondary prevention with ticagrelor compared to clopidogrel: economic evaluation from the public payer's perspective in Poland based on the PLATO trial results.
Pawęska J; Macioch T; Perkowski P; Budaj A; Niewada M
Kardiol Pol; 2014; 72(9):823-30. PubMed ID: 24846362
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of universal and platelet reactivity assay-driven antiplatelet therapy in acute coronary syndrome.
Coleman CI; Limone BL
Am J Cardiol; 2013 Aug; 112(3):355-62. PubMed ID: 23631863
[TBL] [Abstract][Full Text] [Related]
9. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of ticagrelor compared to clopidogrel for the treatment of patients with acute coronary syndrome in Colombia.
Mejía A; Senior JM; Ceballos M; Atehortúa S; Toro JM; Saldarriaga C; Mejía ME; Ramírez C
Biomedica; 2015; 35(4):531-40. PubMed ID: 26844442
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.
Kazi DS; Garber AM; Shah RU; Dudley RA; Mell MW; Rhee C; Moshkevich S; Boothroyd DB; Owens DK; Hlatky MA
Ann Intern Med; 2014 Feb; 160(4):221-32. PubMed ID: 24727840
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of treating acute coronary syndrome patients with ticagrelor for 12 months: results from the PLATO study.
Nikolic E; Janzon M; Hauch O; Wallentin L; Henriksson M;
Eur Heart J; 2013 Jan; 34(3):220-8. PubMed ID: 22719022
[TBL] [Abstract][Full Text] [Related]
13. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor.
Barbieri L; Pergolini P; Verdoia M; Rolla R; Nardin M; Marino P; Bellomo G; Suryapranata H; De Luca G;
Vascul Pharmacol; 2016 Apr; 79():11-15. PubMed ID: 26518440
[TBL] [Abstract][Full Text] [Related]
14. Factors contributing to the lower mortality with ticagrelor compared with clopidogrel in patients undergoing coronary artery bypass surgery.
Varenhorst C; Alström U; Scirica BM; Hogue CW; Åsenblad N; Storey RF; Steg PG; Horrow J; Mahaffey KW; Becker RC; James S; Cannon CP; Brandrup-Wognsen G; Wallentin L; Held C
J Am Coll Cardiol; 2012 Oct; 60(17):1623-30. PubMed ID: 23021325
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of ticagrelor versus clopidogrel for the prevention of atherothrombotic events in adult patients with acute coronary syndrome in Germany.
Theidel U; Asseburg C; Giannitsis E; Katus H
Clin Res Cardiol; 2013 Jun; 102(6):447-58. PubMed ID: 23474908
[TBL] [Abstract][Full Text] [Related]
16. Angiographic outcomes in the PLATO Trial (Platelet Inhibition and Patient Outcomes).
Kunadian V; James SK; Wojdyla DM; Zorkun C; Wu J; Storey RF; Steg PG; Katus H; Emanuelsson H; Horrow J; Maya J; Wallentin L; Harrington RA; Gibson CM
JACC Cardiovasc Interv; 2013 Jul; 6(7):671-83. PubMed ID: 23866179
[TBL] [Abstract][Full Text] [Related]
17. Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70 years and older--rationale and design of the POPular AGE study.
Qaderdan K; Ishak M; Heestermans AA; de Vrey E; Jukema JW; Voskuil M; de Boer MJ; van't Hof AW; Groenemeijer BE; Vos GJ; Janssen PW; Bergmeijer TO; Kelder JC; Deneer VH; ten Berg JM
Am Heart J; 2015 Nov; 170(5):981-985.e1. PubMed ID: 26542508
[TBL] [Abstract][Full Text] [Related]
18. Body Mass Index and Platelet Reactivity During Dual Antiplatelet Therapy With Clopidogrel or Ticagrelor.
Nardin M; Verdoia M; Sartori C; Pergolini P; Rolla R; Barbieri L; Schaffer A; Marino P; Bellomo G; Suryapranata H; De Luca G;
J Cardiovasc Pharmacol; 2015 Oct; 66(4):364-70. PubMed ID: 26065844
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study.
Povsic TJ; Roe MT; Ohman EM; Steg PG; James S; Plotnikov A; Mundl H; Welsh R; Bode C; Gibson CM
Am Heart J; 2016 Apr; 174():120-8. PubMed ID: 26995378
[TBL] [Abstract][Full Text] [Related]
20. Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: A nationwide long-term registry analysis from 2009 to 2014.
Sheikh Rezaei S; Geroldinger A; Heinze G; Reichardt B; Wolzt M
Int J Cardiol; 2017 May; 235():61-66. PubMed ID: 28262344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]